Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Journal of Pharmacology and PharmacotherapeuticsNOW IN
    Article

    A new drug belonging to a novel class of drugs for type 2 diabetes

    Sivagnanam G1★★ Corresponding author

    1. 1Department of Pharmacology, Indira Gandhi Medical College and Research Institute, Kadhirkamam, Puducherry, India.

    CORRESPONDENCE

    Sivagnanam G

    Department of Pharmacology, Indira Gandhi Medical College and Research Institute, Kadhirkamam, Puducherry, India.

    drsivagnanam@gmail.com

    Volume 4, Issue 3 · pp. 224–224 · PUBLISHED 2013 · DOI: 10.4103/0976-500X.114621

    View on J Pharmacol. Pharmacother. original site ↗

    ABSTRACT

    The FDA approval of canagliflozin (Invokana) was based on data involving over 10,285 type 2 diabetes patients, which showed improvement in hemoglobin A1c and fasting plasma glucose levels. Canagliflozin has been tested as monotherapy as well as in combination with metformin, sulphonylurea, pioglitazone, and insulin

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      G, S. (2013). A new drug belonging to a novel class of drugs for type 2 diabetes. Journal of Pharmacology and Pharmacotherapeutics, 4(3), 224–224. https://doi.org/10.4103/0976-500X.114621